$1.23 Billion is the total value of Svennilson Peter's 11 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NGM | Buy | NGM Biopharmaceuticals Inc | $286,665,000 | -18.0% | 18,017,932 | +1.8% | 23.39% | -20.0% |
| NRIX | New | Nurix Therapeutics Inc | $235,848,000 | – | 6,755,881 | +100.0% | 19.24% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- The Column Group II, LP #1
- The Column Group II GP, LP #2
- David Goeddel #3
- The Column Group, LP #4
- The Column Group GP, LP #5
- Ponoi Capital, LP #6
- Ponoi Management, LLC #7
- Tim Kutzkey #8
- Ponoi Capital II, LP #9
- Ponoi II Management, LLC #10
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-04
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CONSTELLATION PHARMCETICLS I | 8 | Q3 2020 | 33.8% |
| GRITSTONE ONCOLOGY INC | 8 | Q3 2020 | 42.2% |
| ARCUS BIOSCIENCES INC | 7 | Q2 2020 | 33.6% |
| NGM BIOPHARMACEUTICALS INC | 6 | Q3 2020 | 69.6% |
| RAPT Therapeutics Inc | 4 | Q3 2020 | 22.3% |
| Revolution Medicines Inc | 3 | Q3 2020 | 22.7% |
| Immune Design Corp. | 2 | Q1 2019 | 20.7% |
| ORIC Pharmaceuticals Inc. | 2 | Q3 2020 | 13.4% |
| Nurix Therapeutics Inc | 1 | Q3 2020 | 19.2% |
View Svennilson Peter's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-08 |
| 4 | 2023-11-17 |
| 4 | 2023-02-01 |
| 4 | 2023-01-25 |
| 4 | 2023-01-23 |
| 4 | 2023-01-17 |
| 4 | 2023-01-12 |
| 4 | 2022-12-14 |
| 4 | 2022-11-23 |
| 4 | 2022-11-07 |
View Svennilson Peter's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.